Skip to main content

Table 6 Multivariable analysis of CMF-treated patients, N = 324*

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

   DFS   OS  
   HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 1.18 (0.87-1.59) 0.28 1.29 (0.87-1.91) 0.20
  High vs. low 1.23 (0.87-1.73) 0.25 1.64 (1.02-2.65) 0.04
Age 41-55 years vs. ≤ 40 years 0.60 (0.43-0.85) 0.004 0.53 (0.33-0.84) 0.007
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.59 (1.07-2.38) 0.02 2.34 (1.31-4.20) 0.01
  Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.92 (1.15-3.22)   1.97 (0.92-4.20)  
Grade Unknown vs. poor 0.83 (0.55-1.25) 0.24 1.05 (0.60-1.84) 0.62
  Well/moderate vs. poor 0.68 (0.43-1.10)   0.74 (0.38-1.46)  
  1. * Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor size and grade were similar with TIMP-1 included.